share_log

Morgan Stanley Initiates Coverage On Senti Biosciences With Equal-Weight Rating, Announces Price Target of $7.5

Morgan Stanley Initiates Coverage On Senti Biosciences With Equal-Weight Rating, Announces Price Target of $7.5

摩根士丹利以同等權重評級啓動對Senti Biosciences的報道,宣佈目標股價爲7.5美元
Benzinga Real-time News ·  2022/10/07 06:12

Morgan Stanley analyst Michael Ulz initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Equal-Weight rating and announces Price Target of $7.5.

摩根士丹利分析師Michael Ulz對森蒂生物科學(納斯達克:SNTI)發起同等權重評級,並宣佈目標價為7.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論